BioSight
Companies
Climb Bio, Inc. logo

CLYM

NASDAQWELLESLEY HILLS, MA
Climb Bio, Inc.

Climb Bio is a clinical-stage biopharmaceutical company developing therapies in areas including budoprutug and CLYM116. The company is advancing multiple product candidates through nonclinical studies and clinical trials with the goal of obtaining regulatory approval and eventual commercialization. Climb Bio is currently preparing to submit investigational new drug applications for its lead candidates.

Price history not yet available for CLYM.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar